Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2011 5
2012 6
2016 1
2018 1
2019 2
2020 1
2021 1
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ. Dörner T, et al. Ann Rheum Dis. 2019 May;78(5):641-647. doi: 10.1136/annrheumdis-2018-214720. Epub 2019 Mar 2. Ann Rheum Dis. 2019. PMID: 30826774 Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjogren's syndrome (pSS) in a double-blind, placebo-controlled, phase II, sing …
OBJECTIVES: To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoc …
Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis.
Wu EY, Oliver M, Scheck J, Lapidus S, Akca UK, Yasin S, Stern SM, Insalaco A, Pardeo M, Simonini G, Marrani E, Wang X, Huang B, Kovalick LK, Rosenwasser N, Casselman G, Liau A, Shao Y, Yang C, Mosa DM, Tucker L, Girschick H, Laxer RM, Akikusa JD, Hedrich CM, Onel K, Dedeoglu F, Twilt M, Ferguson PJ, Ozen S, Zhao Y. Wu EY, et al. J Rheumatol. 2023 Oct;50(10):1333-1340. doi: 10.3899/jrheum.2022-1323. Epub 2023 Jul 1. J Rheumatol. 2023. PMID: 37399459
Spontaneous Model of Sjogren's Syndrome in NOD Mice.
Scuron MD, Fay B, Oliver J, Smith P. Scuron MD, et al. Curr Protoc Pharmacol. 2019 Sep;86(1):e65. doi: 10.1002/cpph.65. Curr Protoc Pharmacol. 2019. PMID: 31539922
The non-obese diabetic (NOD) mouse model is the most widely described and validated method for investigating human primary Sjogren's syndrome (SS) and represents a useful model for translational studies. ...
The non-obese diabetic (NOD) mouse model is the most widely described and validated method for investigating human primary Sjogren' …
GZMK+CD8+ T cells Target a Specific Acinar Cell Type in Sjogren's Disease.
Warner B, Pranzatelli T, Perez P, Ku A, Matuck BF, Huynh K, Sakai S, Abed M, Jang SI, Yamada E, Dominick K, Ahmed Z, Oliver A, Wasikowski R, Easter Q, Magone MT, Baer A, Pelayo E, Khavandgar Z, Gupta S, Kleiner D, Lessard C, Farris A, Martin D, Morell R, Zheng C, Rachmaninoff N, Maldonado-Ortiz J, Qu X, Aure M, Dezfulian M, Lake R, Teichmann S, Barber D, Tsoi L, Sowalsky A, Tyc K, Gudjonsson J, Byrd K, Johnson P, Liu J, Chiorini J. Warner B, et al. Res Sq [Preprint]. 2023 Dec 19:rs.3.rs-3601404. doi: 10.21203/rs.3.rs-3601404/v1. Res Sq. 2023. PMID: 38196575 Free PMC article. Preprint.
Sjogren's Disease (SjD) is a systemic autoimmune disease without a clear etiology or effective therapy. ...This study explores the complex interplay of varied cell types in the salivary glands and their role in the pathology of Sjogren's Disease....
Sjogren's Disease (SjD) is a systemic autoimmune disease without a clear etiology or effective therapy. ...This study explores …
Systemic Disease Associations in a Cohort of Hispanic Patients with Scleritis.
Arruza C, Requejo Figueroa GA, Colón J, Ramirez Marquez E, Puebla G, Ortega D, Pappaterra Rodriguez M, López Fontanet J, Colón A, Ayala Rodríguez SC, Rivera Grana E, Marrero F, Báez E, Santos C, Oliver AL. Arruza C, et al. J Clin Med. 2023 Mar 2;12(5):1969. doi: 10.3390/jcm12051969. J Clin Med. 2023. PMID: 36902755 Free PMC article.
An associated autoimmune disease was present in 33.3% of the patients (rheumatoid arthritis, 22.7%; Sjogren's syndrome, 3.5%; relapsing polychondritis, 2.8%; sarcoidosis, 1.4%; systemic lupus erythematosus, 1.4%; and systemic vasculitis, 0.7%). ...
An associated autoimmune disease was present in 33.3% of the patients (rheumatoid arthritis, 22.7%; Sjogren's syndrome, 3.5%; …
The Beaker phenomenon and the genomic transformation of northwest Europe.
Olalde I, Brace S, Allentoft ME, Armit I, Kristiansen K, Booth T, Rohland N, Mallick S, Szécsényi-Nagy A, Mittnik A, Altena E, Lipson M, Lazaridis I, Harper TK, Patterson N, Broomandkhoshbacht N, Diekmann Y, Faltyskova Z, Fernandes D, Ferry M, Harney E, de Knijff P, Michel M, Oppenheimer J, Stewardson K, Barclay A, Alt KW, Liesau C, Ríos P, Blasco C, Miguel JV, García RM, Fernández AA, Bánffy E, Bernabò-Brea M, Billoin D, Bonsall C, Bonsall L, Allen T, Büster L, Carver S, Navarro LC, Craig OE, Cook GT, Cunliffe B, Denaire A, Dinwiddy KE, Dodwell N, Ernée M, Evans C, Kuchařík M, Farré JF, Fowler C, Gazenbeek M, Pena RG, Haber-Uriarte M, Haduch E, Hey G, Jowett N, Knowles T, Massy K, Pfrengle S, Lefranc P, Lemercier O, Lefebvre A, Martínez CH, Olmo VG, Ramírez AB, Maurandi JL, Majó T, McKinley JI, McSweeney K, Mende BG, Modi A, Kulcsár G, Kiss V, Czene A, Patay R, Endrődi A, Köhler K, Hajdu T, Szeniczey T, Dani J, Bernert Z, Hoole M, Cheronet O, Keating D, Velemínský P, Dobeš M, Candilio F, Brown F, Fernández RF, Herrero-Corral AM, Tusa S, Carnieri E, Lentini L, Valenti A, Zanini A, Waddington C, Delibes G, Guerra-Doce E, Neil B, Brittain M, Luke M, Mortimer R, Desideri J, Besse M, … See abstract for full author list ➔ Olalde I, et al. Nature. 2018 Mar 8;555(7695):190-196. doi: 10.1038/nature25738. Epub 2018 Feb 21. Nature. 2018. PMID: 29466337 Free PMC article.
Ianalumab (VAY736) in primary Sjogren's syndrome: assessing disease activity using multi-modal ultrasound.
Diekhoff T, Fischer T, Schefer Q, Posch MG, Dörner T, Laurent D, Li Y, Wagner FD, Oliver SJ. Diekhoff T, et al. Clin Exp Rheumatol. 2020 Jul-Aug;38 Suppl 126(4):228-236. Epub 2020 Oct 23. Clin Exp Rheumatol. 2020. PMID: 33095139 Free article. Clinical Trial.
OBJECTIVES: To apply serial ultrasound (US) assessments to show effects of ianalumab (anti-BAFF-R monoclonal antibody) on inflamed salivary glands of patients with primary Sjogren's syndrome (pSS). METHODS: In a single-centre, 24-week double-blind study (NCT02149420 …
OBJECTIVES: To apply serial ultrasound (US) assessments to show effects of ianalumab (anti-BAFF-R monoclonal antibody) on inflamed salivary …
The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren's syndrome.
Scuron MD, Fay BL, Connell AJ, Oliver J, Smith PA. Scuron MD, et al. Int Immunopharmacol. 2021 Sep;98:107904. doi: 10.1016/j.intimp.2021.107904. Epub 2021 Jun 29. Int Immunopharmacol. 2021. PMID: 34214886 Free article.
We characterized the potential of parsaclisib to ameliorate autoimmune mechanisms implicated in the pathophysiology of systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). Spontaneous mouse models of SLE and SS were utilized to elucidate the efficacy of o …
We characterized the potential of parsaclisib to ameliorate autoimmune mechanisms implicated in the pathophysiology of systemic lupus erythe …
17 results